Skip to content
Catalyst

PapersPMID:34262417

Effect of Eurycoma longifolia standardised aqueous root extract-Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study.

Food & nutrition research2021The record ↗

findings
6
compound
1
endpoints
6
no difference found
5
PMID:34262417
  1. Finding, moderate evidenceraisesTotal testosterone
  2. Finding, moderate evidenceno difference foundFree testosterone
  3. Finding, moderate evidenceno difference foundSerum insulin-like growth factor 1 (IGF-1)
  4. Finding, moderate evidenceno difference foundGlycated haemoglobin (HbA1c)
  5. Finding, moderate evidenceno difference foundCortisol concentration
  6. Finding, moderate evidenceno difference foundBody mass index
Study, every finding
RCT · 3 months
Dose studied, every finding
100 mg or 200 mg once daily after breakfast for 12 weeks
  • “There was a significant increase (P < 0.05) in the total testosterone for Physta® 100 mg at week 12; for the Physta® 200 mg group, significant increase was seen at week 4 (P < 0.05) and maintained until week 12 (P < 0.001) compared to placebo.”
    Interests
    An author is affiliated with a producer
    Population
    Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, 35 per arm

What did not

  • “There were no significant between-group differences in the free testosterone levels for Physta® 100 and 200 mg compared to placebo at all-time points.”
    Interests
    An author is affiliated with a producer
    Population
    Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, 35 per arm
  • “There were no significant differences between groups in IGF-1 at baseline and week 12 in both Physta® groups compared to placebo, but in Physta® 100 mg group, IGF-1 levels significantly decreased (P < 0.05) at week 12 compared to baseline (Table 4).”
    Interests
    An author is affiliated with a producer
    Population
    Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, week 12 only
  • “There was no significant between-group differences in HbA1c for Physta® groups compared to placebo, but a significant (P < 0.05 and P < 0.01) within-group decrease in HbA1c was seen for both Physta® 200 mg and placebo groups, respectively.”
    Interests
    An author is affiliated with a producer
    Population
    Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, week 12 only
  • “There were no significant differences in the cortisol level in the Physta® groups at baseline and week 12 compared to placebo but a significant (P < 0.01) decrease from baseline is seen at week 12 in the Physta® 200 mg group.”
    Interests
    An author is affiliated with a producer
    Population
    Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, week 12 only
  • “There were no significant within-group or between-group differences in the vital signs, including BMI throughout the study for both Physta® groups.”
    Interests
    An author is affiliated with a producer
    Population
    Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, safety assessment

Study record

Design
randomised controlled trial
Species
human
Population
healthy male volunteers aged 50 to 70 years with testosterone <300 ng/dL
Participants
105
Comparator
placebo
Duration
84 days
Endpoints measured
48